Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Octagon Capital Advisors LP

Q1 2024 · 13F-HR

Octagon Capital Advisors LPholdings as filed

Filed 2024-05-15 · accession 0001214659-24-009309

$834.4M
Reported value
57
Positions
2024-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
03753U106APLSUSDAPELLIS PHARMACEUTICALS INC$165.0M19.8%2,806,980CommonSOLE
02083G100NVLSEURALPINE IMMUNE SCIENCES INC$49.2M5.90%1,241,300CommonSOLE
252828108DNTHDIANTHUS THERAPEUTICS INC$41.4M4.96%1,380,667CommonSOLE
925050106VRNAVERONA PHARMA PLC$38.1M4.57%2,369,000CommonSOLE
26818M108DYNDYNE THERAPEUTICS INC$35.3M4.23%1,242,945CommonSOLE
04272N102AVBPARRIVENT BIOPHARMA INC$34.7M4.16%1,943,836CommonSOLE
457669307INSMINSMED INC$30.9M3.71%1,140,000CommonSOLE
152309100CNTACENTESSA PHARMACEUTICALS PLC$23.3M2.79%2,060,100CommonSOLE
30233G209EYPTEYEPOINT PHARMACEUTICALS INC$22.6M2.71%1,093,503CommonSOLE
67576A100OCULOCULAR THERAPEUTIX INC$22.1M2.64%2,425,000CommonSOLE
86366E106GPCRSTRUCTURE THERAPEUTICS INC$21.7M2.60%506,604CommonSOLE
10806X102BBIOBRIDGEBIO PHARMA INC$21.3M2.56%690,000CommonSOLE
60255C885BRD1EURMIND MEDICINE MINDMED INC$20.2M2.43%2,153,000CommonSOLE
46489V104ISREURPERSPECTIVE THERAPEUTICS INC$17.5M2.10%14,718,422CommonSOLE
21833P301CRBPCORBUS PHARMACEUTICALS HLDGS$15.9M1.90%405,000CommonSOLE
74006W207PRAXPRAXIS PRECISION MEDICINES I$15.9M1.90%260,000CommonSOLE
87990A106TNYATENAYA THERAPEUTICS INC$14.9M1.79%2,854,000CommonSOLE
471871202JSPRJASPER THERAPEUTICS INC$14.7M1.76%500,811CommonSOLE
03589W102ANNXANNEXON INC$14.7M1.76%2,050,000CommonSOLE
23282W605CYTKCYTOKINETICS INC$13.6M1.63%194,000CommonSOLE
008064107AEROVATE THERAPEUTICS INC$11.9M1.43%403,685CommonSOLE
03753U106APLSUSDAPELLIS PHARMACEUTICALS INC$11.8M1.41%200,000CALLSOLE
92790C104VRDNVIRIDIAN THERAPEUTICS INC$10.9M1.30%620,000CommonSOLE
38341P102GOSSGOSSAMER BIO INC$10.8M1.30%9,187,883CommonSOLE
N62509109NAMSNEWAMSTERDAM PHARMA COMPANY$9.6M1.16%408,000CommonSOLE
38000Q102GLYCEURGLYCOMIMETICS INC$9.0M1.08%3,000,000CommonSOLE
45258J102IMVTIMMUNOVANT INC$8.8M1.06%273,289CommonSOLE
877619106TSHATAYSHA GENE THERAPIES INC$8.7M1.04%3,030,000CommonSOLE
00973Y108AKROAKERO THERAPEUTICS INC$8.6M1.03%340,000CommonSOLE
92332V107VTYXUSDVENTYX BIOSCIENCES INC$8.3M0.99%1,501,114CommonSOLE
23256X100CYBIN INC$7.7M0.92%18,604,650CommonSOLE
04280A100ARWRARROWHEAD PHARMACEUTICALS IN$7.2M0.86%250,000CommonSOLE
603170101MLYSMINERALYS THERAPEUTICS INC$7.1M0.85%550,000CommonSOLE
82686Q101SLNSILENCE THERAPEUTICS PLC$6.8M0.82%315,000CommonSOLE
713317105PEPGPEPGEN INC$5.5M0.66%376,117CommonSOLE
92731L106VINCERX PHARMA INC$5.1M0.61%1,000,000CommonSOLE
67080N101NUVBNUVATION BIO INC$5.0M0.60%1,374,870CommonSOLE
71722W107PHATPHATHOM PHARMACEUTICALS INC$4.8M0.58%455,000CommonSOLE
59045L106MERSANA THERAPEUTICS INC$4.5M0.54%1,000,000CommonSOLE
880881107430TERNS PHARMACEUTICALS INC$4.1M0.49%625,000CommonSOLE
31189P102FATEFATE THERAPEUTICS INC$3.8M0.46%520,800CommonSOLE
75974E103RENEO PHARMACEUTICALS INC$3.7M0.45%2,250,000CommonSOLE
032724106ANABANAPTYSBIO INC$3.7M0.45%165,000CommonSOLE
799566104SANASANA BIOTECHNOLOGY INC$3.6M0.43%360,800CommonSOLE
037326105ANTXAN2 THERAPEUTICS INC$3.6M0.43%1,103,000CommonSOLE
019770106ALLOALLOGENE THERAPEUTICS INC$3.2M0.39%720,000CommonSOLE
019818103ALLOVIR INC$3.2M0.38%4,200,000CommonSOLE
92536C103VERUEURVERU INC$2.7M0.32%3,800,000CommonSOLE
75382E109RAPT THERAPEUTICS INC$2.6M0.31%292,000CommonSOLE
65487U108NKTXNKARTA INC$2.6M0.31%240,000CommonSOLE
G4444H101BBOTHELIX ACQUISITION CORP II$2.6M0.31%250,000CommonSOLE
73730P108PSTXUSDPOSEIDA THERAPEUTICS INC$2.3M0.28%736,000CommonSOLE
15673T100IPSCCENTURY THERAPEUTICS INC$2.3M0.27%540,000CommonSOLE
007002108TORCEURADICET BIO INC$1.8M0.22%767,799CommonSOLE
002120202ATYRATYR PHARMA INC$1.4M0.16%700,000CommonSOLE
05280R100AUTLAUTOLUS THERAPEUTICS PLC$1.1M0.13%176,000CommonSOLE
12674W109CABACABALETTA BIO INC$887,1200.11%52,000CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.